Nasdaq:HSCS
HeartSciences Inc.
A high-risk, clinical-stage biotech firm targeting heart failure treatments with significant R&D expenditures and a substantial accumulated deficit.
Key Metrics
Investment Thesis
Bull Case
Investors may consider HSCS for its potential high-return profile if the heart failure drug candidates successfully advance through clinical trials and achieve regulatory approval, offering a speculative entry into a large market with significant unmet needs.
Bear Case
The stock carries extreme downside risk given the total absence of revenue, deepening annual losses, and a negative net change in cash of $4.7M, suggesting the company may require dilutive equity raises or face insolvency before generating any commercial product sales.
About HeartSciences Inc.
HeartSciences Inc. (HSCS) is a clinical-stage biotechnology company focused on developing innovative therapies for heart failure, currently operating with minimal revenue while investing heavily in research and development to advance its drug pipeline.
Analysis
Management Discussion
Despite maintaining a manageable current asset base of $2.2M against total liabilities of $4.0M, the company continues to face widening losses with net profit declining to -$8.8M in 2025. The financial profile reveals heavy reliance on financing cash flows of $2.7M to fund operations and research expenditures of $4.4M while generating no commercial income.
Industry Overview
The heart failure treatment sector is highly competitive with established players, yet remains underserved by approved therapies, creating a challenging but potentially lucrative landscape for innovative biotech entrants that can demonstrate differentiated efficacy and safety profiles.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $5.2K | $18.6K | $4.3K |
| Cost of Revenue | $2.8K | $6.1K | $1.9K |
| Gross Profit | $2.4K | $12.5K | $2.5K |
| Operating Expenses | $6.1M | $6.3M | $8.4M |
| Operating Income | $-6.1M | $-6.3M | $-8.4M |
| R&D | $2.5M | $2.9M | $4.4M |
| G&A | $3.7M | $3.4M | $4.0M |
| Stock-Based Comp | $248.3K | $405.0K | $249.9K |
| Depreciation | $26.9K | $27.9K | $37.6K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Expense | $243.2K | $354.1K | — |
| Pre-Tax Income | $-6.1M | $-6.3M | $-8.4M |
| Income Tax | $241.3K | $299.4K | $412.7K |
| Continuing Ops | $-6.4M | $-6.6M | $-8.8M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-6.4M | $-6.6M | $-8.8M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-6.4M | $-6.6M | $-8.8M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $2.7M | $7.4M | $2.2M |
| Cash & Equivalents | $1.7M | $5.8M | $1.1M |
| Accounts Receivable | — | — | $4.3K |
| Inventory | $676.4K | $629.2K | $650.3K |
| Other Current Assets | $359.8K | $917.1K | $418.7K |
| Long-Term Assets | $590.7K | $2.1M | $2.1M |
| PP&E (Net) | $61.4K | $98.0K | $63.5K |
| Operating Leases | $529.2K | $462.0K | $371.6K |
| Other LT Assets | $0 | $1.6M | $1.6M |
| Total Assets | $3.3M | $9.5M | $4.2M |
| Current Liabilities | $1.8M | $1.8M | $3.7M |
| Accounts Payable | $631.4K | $448.2K | $318.7K |
| Current Leases | $29.5K | $102.3K | $119.5K |
| Other Current Liab | $548.6K | $803.0K | $2.8M |
| Long-Term Liabilities | $1.2M | $434.0K | $314.5K |
| LT Operating Leases | $536.3K | $434.0K | $314.5K |
| Other LT Liab | $687.5K | $0 | $0 |
| Total Liabilities | $3.1M | $2.2M | $4.0M |
| Shareholders' Equity | $230.6K | $7.3M | $205.2K |
| Paid-In Capital | $61.0M | $74.7M | $76.3M |
| Retained Earnings | $-60.8M | $-67.4M | $-76.1M |
| Total L&E | $3.3M | $9.5M | $4.2M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-6.4M | $-6.6M | $-8.8M |
| Non-Cash Adjustments | $1.3M | $573.5K | $2.3M |
| Working Capital Changes | $-718.6K | $-38.5K | $-950.4K |
| Cash from Operations | $-5.8M | $-6.1M | $-7.4M |
| Capital Expenditures | $18.3K | $64.5K | $3.2K |
| Cash from Investing | $-18.3K | $-125.3K | $-30.2K |
| Cash from Financing | $6.5M | $10.3M | $2.7M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $742.2K | $4.1M | $-4.7M |
| Beginning Cash | $918.3K | $1.7M | $5.8M |
| Ending Cash | $1.7M | $5.8M | $1.1M |
Frequently Asked Questions
How does HeartSciences Inc. make money?
The company's operations are centered primarily on research and development activities for cardiovascular therapeutics, supported by general and administrative functions that manage the pre-commercialization phase of its drug candidates.
What are the main risks for HSCS?
Complete lack of revenue generation with three consecutive years of zero sales, significant net losses increasing from $6.4M to $8.8M over the last five years, substantial accumulated deficit of $76.1M limiting financial flexibility, and high burn rate evidenced by negative operating cash flow of $7.4M.
What is HSCS's competitive advantage?
Access to proprietary intellectual property in the heart failure space, specialized expertise in developing therapies for a critical unmet medical need, and a streamlined organizational structure designed to conserve cash during clinical trial execution.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.